- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06934226
Badanie w celu oceny skuteczności i bezpieczeństwa JNJ-77242113 w porównaniu z placebo i ustekinumab u uczestników z łuszczycą umiarkowaną do ciężkiego (ICONIC-ASCEND)
Badanie wieloośrodkowe fazy 3, randomizowane, podwójnie zaślepione, kontrolowane placebo i aktywowane komparnikowe komparator
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Przegląd badań
Status
Warunki
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Barrio Gral Paz Cba Capital, Argentyna, X5000
- Consultora Integral de Salud SRL
-
Buenos Aires, Argentyna, B1643CRO
- Instituto Medico De Alta Complejidad (IMAC)
-
Buenos Aires, Argentyna, C1417EYG
- Mindout Research
-
Buenos Aires, Argentyna, C1425
- Instituto de Neumonologia y Dermatologia
-
CABA, Argentyna, C1061AAS
- CIPREC
-
CABA, Argentyna, C1199ABB
- Hospital Italiano de Buenos Aires
-
CABA, Argentyna, C1055AAO
- Buenos Aires Skin
-
CABA, Argentyna, C1056ABH
- Investigaciones Medicas IMOBA SRL
-
CABA, Argentyna, C1128
- Mautalen Salud e Investigacion
-
Caba, Argentyna, C1122AAF
- Halitus Instituto Medico S.A. - Dermatologia y Estetica
-
Rosario, Argentyna, S2000DBS
- Instituto De Especialidades De La Salud SRL
-
San Fernando, Argentyna, B1646
- MR Medicina Reumatologica
-
San Miguel de Tucumán, Argentyna, T4000
- Instituto de Investigaciones Medicas Tucuman
-
-
-
-
-
Clayton, Australia, 3168
- Monash Medical Centre
-
Coorparoo, Australia, 4151
- Cornerstone Dermatology
-
Greenslopes, Australia, 4120
- Veracity Clinical Research
-
Kogarah, Australia, 2217
- Premier Specialists
-
Melbourne, Australia, 3004
- The Alfred Hospital
-
Melbourne, Australia, 3050
- Royal Melbourne Hospital
-
Mitcham, Australia, 3132
- ISHI dermatology
-
Westmead, Australia, 2145
- Westmead Hospital
-
-
-
-
-
Feldkirch, Austria, 6800
- LKH Feldkirch
-
Linz, Austria, 4020
- Kepler Universitatsklinikum GmbH
-
Sankt Pölten, Austria, 3100
- Universtitatsklinikum St Poelten
-
Vienna, Austria, 1090
- Allgemeines Krankenhaus der Stadt Wien
-
-
-
-
-
Brussels, Belgia, 1090
- UZ Brussel
-
Ghent, Belgia, 9000
- Ghent University Hospital
-
Ghent, Belgia, 9000
- AZ St. Lucas
-
Leuven, Belgia, 3000
- Universitair Ziekenhuis Leuven
-
Liège, Belgia, 4000
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
-
Maldegem, Belgia, 9990
- Dermatologie Maldegem
-
-
-
-
-
Aalborg, Dania, 9100
- Aalborg Sygehus Syd
-
Aarhus, Dania, 8200
- Aarhus University Hospital
-
Hellerup, Dania, 2900
- Gentofte Hospital
-
København NV, Dania, 2400
- Bispebjerg Hospital
-
Odense, Dania, 5000
- Odense University Hospital
-
Roskilde, Dania, 4000
- Sjællands University hospital
-
-
-
-
-
Alicante, Hiszpania, 03010
- Hosp. Gral. Univ. Dr. Balmis
-
Barakaldo, Hiszpania, 48902
- Hosp. Univ. de Cruces
-
Barcelona, Hiszpania, 08036
- Hosp. Clinic de Barcelona
-
Granada, Hiszpania, 18016
- Hosp. Univ. San Cecilio
-
Madrid, Hiszpania, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Hiszpania, 28006
- Hosp. Univ. de La Princesa
-
Madrid, Hiszpania, 28002
- Grupo Dermatologico Y Estetico Pedro Jaen
-
Manises, Hiszpania, 46940
- Hosp. de Manises
-
Santiago Compostela, Hiszpania, 15706
- Hosp. Clinico Univ. de Santiago
-
Seville, Hiszpania, 41009
- Hosp. Virgen Macarena
-
Seville, Hiszpania, 41014
- Hosp. Ntra. Sra. de Valme
-
Valencia, Hiszpania, 46026
- Hosp. Univ. I Politecni La Fe
-
Villajoyosa, Hiszpania, 03570
- Hosp. de La Marina Baixa
-
Zaragoza, Hiszpania, 50009
- Hosp. Clinico Univ. Lozano Blesa
-
Zaragoza, Hiszpania, 50009
- Hosp. Univ. Miguel Servet
-
-
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Kanada, A1E 1V4
- Skincare Studio Inc Dermatology Clinical Trials
-
-
Ontario
-
Ajax, Ontario, Kanada, L1S7K8
- CCA Medical Research Corporation
-
Barrie, Ontario, Kanada, L4M 7G1
- SimcoDerm Medical and Surgical Dermatology Centre
-
Hamilton, Ontario, Kanada, L8N 1Y2
- Dermatrials Research
-
London, Ontario, Kanada, N6A 5R9
- Lovegrove Dermatology
-
Markham, Ontario, Kanada, L3P 1X3
- Lynderm Research Inc.
-
Waterloo, Ontario, Kanada, N2J 1C4
- Alliance Clinical Trials
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X 2V1
- Innovaderm Research Inc.
-
Québec, Quebec, Kanada, G1W 4R4
- The Centre de recherche Saint-Louis
-
-
-
-
-
Augsburg, Niemcy, 86179
- Klinikum Augsburg
-
Bad Bentheim, Niemcy, 48455
- Fachklinik Bad Bentheim
-
Berlin, Niemcy, 10789
- ISA - Interdisciplinary Study Association GmbH
-
Bonn, Niemcy, 53127
- Universitatsklinikum Bonn
-
Bramsche, Niemcy, 49565
- Studienzentrum an der Hase GbR
-
Darmstadt, Niemcy, 64283
- Rosenpark Research GmbH
-
Dresden, Niemcy, 01307
- Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
-
Friedrichshafen, Niemcy, 88045
- Derma-Study-Center Friedrichshafen GmbH
-
Kiel, Niemcy, 24105
- Universitaetsklinikum Schleswig Holstein Campus Kiel
-
Langenau, Niemcy, 89129
- Studienzentrum Dr Schwarz Germany
-
Mahlow, Niemcy, 15831
- Dermatologie Mahlow
-
Mainz, Niemcy, 55128
- Gemeinschaftspraxis Dres. Quist
-
Münster, Niemcy, 48149
- Universitaetsklinikum Muenster
-
Witten, Niemcy, 58453
- Hautarztpraxis
-
-
-
-
-
Bialystok, Polska, 15 375
- Specderm Poznanska sp j
-
Bialystok, Polska, 15-351
- Osteo-Medic s.c A. Racewicz, J Supronik
-
Elblag, Polska, 82 300
- Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
-
Katowice, Polska, 40 568
- Care Clinic Sp z o o
-
Krakow, Polska, 30 002
- Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
-
Lodz, Polska, 90-265
- Dermed Centrum Medyczne Sp z o o
-
Olsztyn, Polska, 10-117
- Etyka Osrodek Badan Klinicznych
-
Poznan, Polska, 60 529
- SOLUMED Centrum Medyczne
-
Skierniewice, Polska, 96 100
- Velocity Nova Sp z o o
-
Warsaw, Polska, 02 661
- Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
-
Warsaw, Polska, 02 953
- Klinika Ambroziak Dermatologia
-
Wroclaw, Polska, 52 416
- Centrum Medyczne Oporow
-
Wroclaw, Polska, 51 685
- WroMedica I Bielicka A Strzalkowska s c
-
-
-
-
-
Guimarães, Portugalia, 4835 044
- Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
-
Leiria, Portugalia, 2410 197
- Unidade Local De Saude Da Regiao De Leiria Epe
-
Lisbon, Portugalia, 1169 050
- Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
-
Lisbon, Portugalia, 1998 018
- Hosp. Cuf Descobertas
-
Porto, Portugalia, 4099 001
- Ulssa Hosp. Santo Antonio
-
-
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35244
- Cahaba Research Inc
-
-
California
-
Encinitas, California, Stany Zjednoczone, 92024
- California Dermatology & Clinical Research Institute
-
Encino, California, Stany Zjednoczone, 91436
- T Joseph Raoof Md Inc
-
Fountain Valley, California, Stany Zjednoczone, 92708
- First OC Dermatology
-
Oceanside, California, Stany Zjednoczone, 92056
- Dermatologist Medical Group of North County, Inc.
-
Rocklin, California, Stany Zjednoczone, 95765
- NorCal Clinical Research
-
Sacramento, California, Stany Zjednoczone, 95815
- Integrative Skin Science and Research
-
San Diego, California, Stany Zjednoczone, 92103
- MedDerm Associates
-
Santa Ana, California, Stany Zjednoczone, 92701
- Southern California Dermatology
-
Sylmar, California, Stany Zjednoczone, 91342
- Olive View-UCLA Education & Research Institute
-
-
Connecticut
-
Farmington, Connecticut, Stany Zjednoczone, 06030
- University of Conn Health Center
-
-
Florida
-
Miami, Florida, Stany Zjednoczone, 33155
- Bioclinical Research Alliance Inc.
-
Miami, Florida, Stany Zjednoczone, 33126
- Driven Research LLC
-
Ocala, Florida, Stany Zjednoczone, 34470
- Renstar Medical Research
-
Tampa, Florida, Stany Zjednoczone, 33613
- Forcare Clinical Research Inc
-
-
Georgia
-
Alpharetta, Georgia, Stany Zjednoczone, 30022
- Hamilton Research LLC
-
-
Illinois
-
Skokie, Illinois, Stany Zjednoczone, 60076
- Northshore Medical Group
-
-
Indiana
-
Plainfield, Indiana, Stany Zjednoczone, 46168
- Indiana Clinical Trial Center
-
-
Iowa
-
Iowa City, Iowa, Stany Zjednoczone, 52242
- University of Iowa
-
-
Kentucky
-
Bowling Green, Kentucky, Stany Zjednoczone, 42104
- Equity Medical
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02111
- Tufts Medical Center
-
Brighton, Massachusetts, Stany Zjednoczone, 02135
- Metro Boston Clinical Partners
-
-
Michigan
-
Caledonia, Michigan, Stany Zjednoczone, 49316
- The Derm Institute of West Michigan
-
Detroit, Michigan, Stany Zjednoczone, 48202
- Henry Ford Hospital
-
Fort Gratiot, Michigan, Stany Zjednoczone, 48059
- Hamzavi Dermatology
-
Troy, Michigan, Stany Zjednoczone, 48084
- Somerset Skin Centre
-
-
Minnesota
-
New Brighton, Minnesota, Stany Zjednoczone, 55112
- Minnesota Clinical Study Center
-
-
Missouri
-
Kirksville, Missouri, Stany Zjednoczone, 63501
- Cleaver Dermatology
-
Saint Joseph, Missouri, Stany Zjednoczone, 64506
- MediSearch Clinical Trials
-
-
New York
-
New York, New York, Stany Zjednoczone, 10075
- Sadick Research Group
-
New York, New York, Stany Zjednoczone, 10028
- Mount Sinai Doctors Dermatology
-
-
North Carolina
-
Wilmington, North Carolina, Stany Zjednoczone, 28405
- Wilmington Dermatology Center
-
-
Ohio
-
Boardman, Ohio, Stany Zjednoczone, 44512
- Optima Research
-
Mayfield Heights, Ohio, Stany Zjednoczone, 44124
- Apex Dermatology Mayfield Heights
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97210
- Oregon Dermatology and Research Center
-
Portland, Oregon, Stany Zjednoczone, 97201
- Oregon Medical Research Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19114
- Clinical Research Philadelphia
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15213
- UPMC Department of Dermatology
-
-
South Dakota
-
Rapid City, South Dakota, Stany Zjednoczone, 57702
- Health Concepts
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37211
- Advanced Research Experts PLLC
-
-
Texas
-
Arlington, Texas, Stany Zjednoczone, 76011
- Arlington Research Center, Inc.
-
Dallas, Texas, Stany Zjednoczone, 75231
- Modern Research Associates PLLC
-
Houston, Texas, Stany Zjednoczone, 77004
- Center for Clinical Studies 1
-
San Antonio, Texas, Stany Zjednoczone, 78218
- Texas Dermatology and Laser Specialists
-
San Antonio, Texas, Stany Zjednoczone, 78213
- Progressive Clinical Research
-
Webster, Texas, Stany Zjednoczone, 77598
- Center for Clinical Studies
-
-
Utah
-
West Valley City, Utah, Stany Zjednoczone, 84120
- Kalo Clinical Research
-
-
Washington
-
Mill Creek, Washington, Stany Zjednoczone, 98012
- Frontier Derm Partners CRO, LLC
-
-
-
-
-
Budapest, Węgry, 1036
- Obudai Egeszsegugyi Centrum Kft
-
Budapest, Węgry, 1152
- Uno Medical Trials Ltd.
-
Debrecen, Węgry, 4032
- Debreceni Egyetem Klinikai Kozpont
-
Debrecen, Węgry, 4031
- Derma-B Kft
-
Gyula, Węgry, 5700
- Synexus Magyarorszag Kft
-
Gyöngyös, Węgry, 3200
- Gyongyosi Bugat Pal Korhaz
-
Hódmezővásárhely, Węgry, 6800
- Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
-
Kaposvár, Węgry, 7400
- Somogy Varmegyei Kaposi Mor Oktato Korhaz
-
Kecskemét, Węgry, 6000
- Bacs-kiskun Megyei Korhaz
-
Szolnok, Węgry, 5000
- Allergo-Derm Bakos Kft.
-
Veszprém, Węgry, 8200
- Medmare Egeszsegugyi Es Szolgaltato Bt.
-
-
-
-
-
Dudley, Zjednoczone Królestwo, DY1 2HQ
- Dudley Group NHS Foundation Trust
-
Harrow, Zjednoczone Królestwo, HA1 3UJ
- London North West University Healthcare NHS Trust
-
Kings Lynn, Zjednoczone Królestwo, PE30 4ET
- The Queen Elizabeth Hospital NHS Foundation Trust
-
London, Zjednoczone Królestwo, SE1 9RT
- Guys and St Thomas NHS Foundation Trust
-
Reading, Zjednoczone Królestwo, RG1 5AN
- Royal Berkshire Hospital
-
Salford, Zjednoczone Królestwo, M6 8HD
- Salford Royal Hospital
-
Southampton, Zjednoczone Królestwo, So166yd
- University Hospital Southampton
-
Wakefield, Zjednoczone Królestwo, WF1 4DG
- Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
- Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
- Total psoriasis area and severity index (PASI) >=12 at screening and baseline
- Total investigator global assessment (IGA) >=3 at screening and baseline
- Candidate for phototherapy or systemic treatment for plaque psoriasis
Exclusion Criteria:
- Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
- Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
- Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
- Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Arm 1: JNJ 77242113
Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind. |
JNJ-77242113 will be administered orally. Matching placebo will be administered subcutaneously. |
|
Komparator placebo: Arm 2: Placebo
Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104. |
JNJ-77242113 will be administered orally. Matching placebo will be administered subcutaneously. Matching placebo will be administered orally. |
|
Aktywny komparator: Arm 3: Ustekinumab
Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28. |
JNJ-77242113 will be administered orally. Matching placebo will be administered orally. Ustekinumab will be administered subcutaneously.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
Ramy czasowe: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Ramy czasowe: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 16
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
Ramy czasowe: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Ramy czasowe: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
Ramy czasowe: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
Ramy czasowe: Week 28
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
Ramy czasowe: Week 28
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
Ramy czasowe: Week 28
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 28
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
Ramy czasowe: Week 16
|
PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
Ramy czasowe: Week 16
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Ramy czasowe: Up to Week 108
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product & is medically important. |
Up to Week 108
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
Ramy czasowe: Week 16
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
Ramy czasowe: Baseline up to Week 16
|
DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Baseline up to Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
Ramy czasowe: Week 16
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
Ramy czasowe: Baseline up to Week 16
|
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA. |
Baseline up to Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
Ramy czasowe: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
Ramy czasowe: Baseline up to Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
Ramy czasowe: Baseline up to Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
Ramy czasowe: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
Ramy czasowe: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
Ramy czasowe: Baseline up to Week 28
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
Ramy czasowe: Week 28
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
Ramy czasowe: Baseline up to Week 16
|
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA. |
Baseline up to Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
Ramy czasowe: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
Ramy czasowe: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Ramy czasowe: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 16
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 77242113PSO3006
- 77242113PSO3006 (Inny identyfikator: Janssen Research & Development, LLC)
- 2024-515706-77-00 (Identyfikator rejestru: EUCT number)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .